PCL Research & Manufacturing is an integrated CRO/CDMO: solid-state R&D, GMP analysis and non-GMP manufacturing under one roof. Its laboratory, certified by AIFA and inspected by the FDA, handles high-potency APIs up to OEB5 and controlled substances — one of the few in Europe to combine all three.
PCL Research & Manufacturing is one of the few laboratories in Europe that hold all three, so a potent, scheduled API can be analysed end to end without splitting the work across sites.
Certified by AIFA, the Italian Medicines Agency, and inspected by the U.S. FDA.
Certificate IT/90/H/2025 GMP Analysis OEB5Analysis and handling of HPAPIs up to OEB5, with containment and procedures built for the tightest exposure limits.
Up to OEB5 HPAPI analysis MoHAuthorized by the Italian Ministry of Health to receive, store and analyse narcotic and psychotropic APIs.
Ministry of Health authorization Controlled substancesWhere they meet: a potent, controlled API analysed under GMP, with one quality system, one register and one chain of custody.
PCL Research & Manufacturing s.r.l. is a privately owned CRO/CDMO providing reliable solutions to optimise and control the crystallisation process of Active Pharmaceutical Ingredients — since 2005.
Our mission is to support clients during drug development, helping them reduce batch failure, avoid costly crystallisation issues and offer greater confidence in drug quality. We support you from early-phase discovery to kilogram-scale non-GMP supply.
We are a high-performing team of trained chemists and analysts with more than 20 years of experience in API crystallization, caring about results and innovation based on sound science.
Discover the CompanyFrom analytical characterization to kilogram-scale non-GMP manufacturing — complete pharmaceutical development support.
Complete range of GMP-certified analytical capabilities. FDA inspected, authorized for HPAPI handling up to OEB5.
From co-crystal discovery to process optimization — unique solid-state experience. Data-driven, de-risk your API development.
Contract development & non-GMP manufacturing from development batches to kilogram-scale supply. Robust scale-up transfer.
We are authorized by the Italian Ministry of Health to study, produce and analyze controlled substances and highly potent APIs up to OEB5 — with dedicated containment and handling protocols that keep your most demanding molecules safe at every step.
Our analytical facility operates under strict regulatory compliance, giving pharmaceutical partners worldwide complete confidence in quality and integrity.
Our analytical facility has been inspected by the U.S. Food & Drug Administration, confirming adherence to international pharmaceutical quality standards.
Our analytical department is certified to work according to GMP by AIFA. Certified: XRPD, FT-Raman, FT-IR and Particle Size Distribution.
Authorized by the Italian Ministry of Health for the study, production and analysis of controlled substances and HPAPIs up to OEB5.
A single A4 sheet covering our GMP-certified analytics, controlled-substances authorisation, HPAPI containment to OEB5 and full structure determination — plus two representative engagement profiles with typical scope and timelines. Written for the people who need to compare suppliers quickly.
Print-ready A4 · English · no form required
The full picture: why the solid form decides whether a drug works, what each of our four capabilities covers, four anonymised engagements showing the work in practice, and how a programme runs from first conversation to final report.
12 pages · print-ready A4 · English · no form required
Scientific publications, industry news and company announcements from PCL Research & Manufacturing.
A practical, step-by-step framework for teams who need defensible solid-form data, not just a longer polymorph report.
A single diffractogram cannot confirm miscibility, physical stability, or manufacturability.
Rifaximin's polymorph dispute shows that chemical identity alone does not guarantee commercial or regulatory equivalence.
Polymorph screening tells you what a molecule did in the lab. CrystallQ, the decision-support platform PCL Research & Manufacturing is developing, is built to tell you where to look first: the probability of a hydrate, the likely salt or co-crystal outcome across a list of pharmaceutically acceptable co-formers, plausible packing motifs, and an experimental matrix targeted on the regions that matter.
It does not replace the screen. It aims it — fewer blind routes, a smaller experimental space, and a documented rationale for the conditions you chose.
Every model is measured against the naive baseline before it ships, and anything that does not beat that baseline is removed rather than reported.
Models are validated retrospectively against published solid-form data. Extension to PCL Research & Manufacturing's own experimental archive is in progress, under the confidentiality terms agreed with each client.
The number of polymorphic forms.
That number is not a property of the molecule alone: it is a property of the molecule and the screen applied to it. The same compound yields different counts under an 80-sample propensity screen and a 600-sample exhaustive one, so a model trained on published form counts largely learns how much its authors invested. We built such a score, measured it, found it no better than the population prior, and removed it. We would rather tell you that than have you find out.
Deterministic, versioned models do the calculating. Language models never produce a number that reaches a technical report. Every output destined for a client is approved by a named reviewer, and no one can approve work they initiated themselves.
Built to the principles of EU GMP Annex 11 and the draft Annex 22 on AI, with AI literacy obligations under Regulation (EU) 2024/1689 already in place. Your data is never used to train anything for anyone else. How we govern AI
If you have a molecule that has resisted conventional screening, we would like to test CrystallQ against it — with acceptance criteria fixed before we see your data, and we will share what we find, including where we were wrong.
Join the CrystallQ pilotAn API that is stable on its own can still fail in the tablet. Our new program tests your solid form against the excipients, the process and the moisture of the product, looking for chemical degradation and solid-state changes such as salt disproportionation or polymorphic conversion, before the formulation is locked.
Discover the programA practical guide to choosing the solid form of an API: polymorphs, hydrates, the amorphous state, salts and co-crystals — what each one changes, when each is available, and what it costs to decide late. Includes a side-by-side comparison of the five approaches.
Read the white paperNine fairs, conferences and partnering meetings on both sides of the Atlantic: CPHI Milan, AAPS PharmSci 360, DCAT Week, BIO-Europe Spring, the BCA Spring Meeting, the Global DDF Summit, BOS Basel, Farmaforum and CPHI Frankfurt. The full calendar, with dates, venues and a meeting request for each event, is on the new Events page.
See the events calendarWe'll also attend DCAT Week 2027 — the premier business-development event for the global pharmaceutical manufacturing value chain — in New York City, 15–18 March 2027. Schedule a one-to-one meeting to explore how PCL Research & Manufacturing can support your development pipeline.
Request a meeting at DCATPCL Research & Manufacturing extends its analytical portfolio with full structure determination and absolute configuration assignment. The offer combines Single Crystal XRD (lab instrument or synchrotron based), Neutron Diffraction for precise hydrogen positions and hydrogen-bond networks, and Micro Electron Diffraction for structures from sub-micron crystals that cannot be grown any larger. Together they resolve chirality, confirm salt versus co-crystal nature and support patent and regulatory filings.
Explore the serviceUnderstanding solid-state properties early helps avoid manufacturing problems and improve drug performance and bioavailability.
PCL Research & Manufacturing expands controlled substance analytical services with full OEB5 authorization from the Italian Ministry of Health.
How robust process development de-risks the transition from lab-scale to non-GMP API manufacturing.
Analytical testing, solid form screening, or non-GMP development & manufacturing — our team of experts is ready to support your drug development program.
Via F.S. Fabri, 127/1 — 40059 Medicina (BO), Italy
Via Della Cooperazione, 29 — 40059 Medicina (BO), Italy
We'll respond within 24 business hours.